Conditions: Opioid-induced Constipation
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 26
Healthy volunteers: no

Brief summary:
This is an open label compassionate use study of subcutaneously administered methylnaltrexone (MNTX) in participants with advance medical illness and opioid-induced constipation.

Detailed description:

Arms:
arm 1: Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.

Interventions: intervention 1: Methylnaltrexone
Intervention descriptions: intervention 1: Methylnaltrexone will be administered as per the dose and schedule specified in the arm.

Protocol document: